Barr’s Bijuva Estrogen Cream Is “Not Approvable” At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will require additional clinical evidence pertaining to an unmet endpoint, Barr says. Two of three endpoints for the synthetic conjugated estrogens cream were met during clinical studies; the third was modified at FDA’s guidance after the trials began, the company says.
You may also be interested in...
Barr Kicks Off Enjuvia Detailing Two Years After First Approval
Subsidiary Duramed will support the estrogen therapy launch with 250 sales reps.
Barr Kicks Off Enjuvia Detailing Two Years After First Approval
Subsidiary Duramed will support the estrogen therapy launch with 250 sales reps.
Barr Closes Another Chapter In Quest For Generic Premarin
The company will withdraw its ANDA for a version of Wyeth’s conjugated estrogen product after an appeals court affirms decision against raw materials supplier. Barr says it “will continue to review all options regarding its efforts to bring a generic version” of Premarin to market.